参考文献/References:
[1] Van Meerbeeck JP,Fennell DA,De Ruysscher DK.Small-cell lung cancer.Lancet,2011,378(9804):1741-1755.
[2] Patel AR,Wedzicha JA,Hurst JR.Reduced lung-cancer mortality with CT screening.N Engl J Med,2011,365(21):2035.
[3] Sox HC.Better evidence about screening for lung cancer.N Engl J Med,2011,365(5):455-457.
[4] Heuvers ME,Stricker BH,Aerts JG.Generalizing lung-cancer screening results.N Engl J Med,2012,366(2):192-193.
[5] Xie Y,Minna JD.A lung cancer molecular prognostic test ready for prime time.Lancet,2012,379(9818):785-787.
[6] Yasuda H,Kobayashi S,Costa DB.EGFR exon 20 insertion muta-tions in non-small-cell lung cancer:preclinical data and clinical implications.Lancet Oncol,2012,13(1):e23-3 t.
[7] Wang W,Li Q,Takeuchi S,et al.Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.Clin Cancer Res,2012,18(6):1663-1671.
[8] Su KY,Chen HY,Li KC,et al.Pretreatment epidermal growthfactor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.J Clin Oneol,2012,30(4):433-440.
[9] Politi K,Lynch TJ.Two sides of the same coin:EGFR exon 19 deletions and insertions in lung cancer.Clin Cancer Res,2012,18(6):1490-1492[2012-03-15].http://www.ncbi.nlm.nih.gov/pubmed?term=Politi%20K%2C%20Lynch%20TJ.%20Two%20sides%20of%20the%20same%20coin%3A%20EGFR%20ex-on%2019%20deletions%20and%20insertions%20in%20lung%20cancer.[published online ahead of print Feb 8,2012].
[10] Pirker R,Pereira JR,yon Pawel J,et al.EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer:analysis of data from the phase 3 FLEX study.Lancet Oncol,2012,13(1):33-42.
[11] Kim HR.Shim HS,Chung JH,et al.Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.Cancer, 2012.118(3):729-739.
[12] Hnn CB,Ma JT.Li F, et a1.EGFR and KRASmutations and altered o-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.Cancer Lett 2012. 314(1):63-72.
[13] Yoshioka H,Yamameto S,Hanaoka H,el a1.In rive therapeutic effect of CDH3/P-cedherin-targeting radioimmunotherapy[J/OL]. Cancer Immanol lmmunother,2012,61[2012-03-15].http://www.nebi.nlm.nih.gov/pubmed?term=Yoshioka%20H%2C%20Yamamoto%20S%2C%20Haunoka%20H%2c%20et%2C%20in%20vivo%20therapeutic%20effect%200f%20CDH3%2HLeedherin-targeting%20redioimmunotherapy.[published online ahead of print Jan 6.2012].
[14] D’Arienzo M,Cieone F,Chiacchiararelli L el a1.Three dimensional patient-specific dosimetty in radioimmunotherapy with 90Y ihritumomab-tiuxetan.Cancer Biother Radiopharm,2012,27(2):124-133[2012-03-15]. http://www.ncbi.nlm.nih.gov/pubmed?term=D’Arien-zo%20M%2C%20Cleone%20F%2C%20Chiacchiarareili%20L%2C%20et%20n1.%20Three-dimemional%20patient-specific%20dosimctry%20in%20redioirnmunothempy%20with%2090Y-ibri-tumomab-tiuxelan.%20.[published online aheed of print Jan27.2014
[15] Khawli LA,Hu P,Epstein AL.Cytokine,ehemokine,and co-stimu-latory fusion proteins for the immunotherapy of solid tumom.Handb Exp Pharmacol.2008.181:291-328.
[16] Yi LK,Ju DW,Chen WP.et a1.131I-chTNT radioimmalmtherapy of 43 patients with advanced lung cancer.Cancer Biother Radiopharm, 2006,21(1):5-14.
[17] Chen sL,Yu LK,Jiang CY.et a1.Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment redioimmunotherapy in patients with advanced lung cancer.Clin Oncol,2005,23(7): 1538-1547.
[18] BoeHnan OC,Koppe MJ,Postema EJ.el a1.Radionuclide therapy of cancer with radiolaheled antibodies.Antieancer Agents Med Chem,2007,7(3):335-343.
[19] McLendnn RE,Akabani G,Friedman HS,et a1.Tumor resection cavity administered iodine-131-labeled antitenasein 81C6 tadioimmunothempy in patients with malignant glioma:neuropathology aspects.Nucl Med Bid,2007,34(4):加5-413.
[20] Street HH,Goris ML Fisher GA,etal.Phase I study of of 131I-chimeric (eh)TNT-l/B monoclonal antibody for the treatment of advanced coloncancer.Cancer Biother Radiophann,2006,2l(3):243-256.
[21] Hdeib A,Slosh AE.Convection-enhanced delivery of 131I-chTNT.1, B mAB for treatment of hish-grade adult glinmas.Expert Opin Biol Ther,201l,11(6):799-806.
[22] Yan Y,Zhang HF.Zhang YD.el a1.Trandection of the human sodium/iodide symperter(NIS)gene with lipesomes and the expression of the NIS pmtein in human lung A549 cancer cells.Chin J CLin Oncol,2008,5(1):30-34.
[23] Guo R,Zhang YF.Liang S,el a1.Sodium butyrate enhances the expression of baeulovims-mediated sodium/iodide symportcr gene in A549 lung adenocareinoma cells.Nucl Med Commun,2010,31(10):916-921,
[24] Niu G,Krager KJ.Graham MM,et a1.Noninvasive radiologicaI imaging of pulmonary gene transfer and expression using the human sodium iodide symporter.Eur J Nucl Med Mol Imaging.2005.32(5):534-540.
[25] Shi Yz,Zhang J,Liu ZL et a1.Adenovims.mediated and tumorspecific transgene expression of the sodium-iodide symporter from the human telomerase reverse transcriptase promoter enhanees killing of lung eancer cell line in vitro.Chin Med J(Engl),2010.123(15):2070-2076.
[26] Kang do Y,Lee HW,Choi PJ,et a1.Sodium/iodide symperter expression in primary lung cancer with glucose transporter l expression.Pathol Int.2009.59(2):73-79.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]拓飞,张庆,张京,等.2014年度全国放射性核素γ能谱分析质量控制比对[J].国际放射医学核医学杂志,2015,39(5):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
tuo fei,zhang qing,zhang jing,et al.nationwide intercomparison for radionuclide analyses through γ-spectrometry method in 2014[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
[6]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[7]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[8]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[9]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[10]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[11]彭武和,程静,曹庆东.核素肺通气/灌注显像在肺栓塞诊断中的现状及进展[J].国际放射医学核医学杂志,2012,36(2):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
PENG Wu-he,CHENG Jing,CAO Qing-dong.Present situation and development of the nuclide lung ventilation/perfusion imaging in diagnosis of lung embolim[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
[12]黄帆,高阳,张玉民,等.新型渗透性水凝胶作为载体用于肿瘤的放射性核素植入治疗[J].国际放射医学核医学杂志,2017,41(2):81.[doi:10.3760/cma.j.issn.1673-4114.2017.02.001]
Huang Fan,Gao Yang,Zhang Yumin,et al.New permeable hydrogel for tumor radiotherapy in situ[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):81.[doi:10.3760/cma.j.issn.1673-4114.2017.02.001]
[13]高之晔,韩星敏.放射性核素标记的胆碱在PET/CT肿瘤显像中的应用[J].国际放射医学核医学杂志,2018,(3):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
Gao Zhiye,Han Xingmin.Application of radionuclide-labeled choline in PET/CT tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]